Former Global President, Emerging Markets, brings over 30 years of expertise to LianBio Board of Directors

SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)--LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced the appointment of Susan Silbermann to the company�s Board of Directors.

�Susan brings to the board remarkable leadership experience and a strong track record of operational execution across therapeutic areas, drug modalities and geographies,� said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. �She will be a tremendous asset to LianBio as we continue to advance our diverse pipeline of potentially transformative medicines for patients in China and throughout Asia.�

During a 30 year career at Pfizer, Ms. Silbermann held numerous leadership positions in marketing, commercial development and general management in the U.S. and international markets. Prior to her retirement in May 2021, Ms. Silbermann chaired Pfizer�s Global COVID-19 Task Force. At the same time, Ms. Silbermann served as Pfizer�s Global President, Emerging Markets, where she oversaw operations across marketing, medical, sales, access and government affairs in China, Asia, Latin America, Africa and the Middle East. In this role, she designed and implemented a new innovation-focused organization in China, working in close collaboration with both the central government and the provinces to address their specific healthcare needs.

From 2012 until 2018, Ms. Silbermann served as President and General Manager of Pfizer Vaccines. In this role, Ms. Silbermann was responsible for both the commercial development and operational management of Pfizer�s portfolio of preventative and therapeutic vaccines. She was also a member of the board of Gavi, the Vaccine Alliance from 2017 until 2020. From 2008 until 2012, she was the regional president of Latin America within Pfizer�s Emerging Markets Business Unit where she managed Pfizer�s pharmaceutical operations in this diverse region.

�LianBio is leading the next generation of innovation-focused biotech companies in China,� said Ms. Silbermann. �I look forward to collaborating with the board and LianBio team to continue the important work of bringing therapeutic advances to patients in Asia.�

Ms. Silbermann earned a bachelor�s degree in biology and French from Tufts University, and master's degrees in international business and French studies from the Stern Graduate School of Business and the Institute of French Studies at New York University.

About LianBio

LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit www.lianbio.com.

Contacts

For investor inquiries, please contact:
Elizabeth Anderson, VP Communications and Investor Relations

E: [email protected]
T: +1 646 655 8390

For media inquiries, please contact:
Katherine Smith, CanaleComm

E: [email protected]
T: +1 619 849 5378